B. Clotet

发表

European guidelines on the clinical management of HIV-1 tropism testing.

A. Wensing, H. Walter, R. Kaiser, 2011, The Lancet. Infectious diseases.

Consensus statement of the European guidelines on clinical management of HIV-1 tropism testing

H. Walter, R. Kaiser, K. Korn, 2010, Journal of the International AIDS Society.

Cetylpyridinium Chloride Mouthwash to Reduce Shedding of Infectious SARS-CoV-2: A Double-Blind Randomized Clinical Trial

D. Raïch-Regué, B. Clotet, O. Mitjà, 2022, Journal of dental research.

Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection

R. Paredes, B. Clotet, J. Segalés, 2021, Cell Reports Medicine.

Efficacy of etravirine combined with darunavir or other ritonavir‐boosted protease inhibitors in HIV‐1‐infected patients: an observational study using pooled European cohort data

J. Lundgren, V. Calvez, F. Ceccherini‐Silberstein, 2015, HIV medicine.

Monitoring adherence to HIV therapy.

R. Paredes, B. Clotet, D. Burger, 1999, Archives of internal medicine.

Herb-drug interaction between Echinacea purpurea and darunavir/ritonavir in HIV-infected patients

B. Clotet, E. Negredo, M. Barbanoj, 2010, Antimicrobial Agents and Chemotherapy.

HIV-1 Subtype Is an Independent Predictor of Reverse Transcriptase Mutation K65R in HIV-1 Patients Treated with Combination Antiretroviral Therapy Including Tenofovir

A. De Luca, M. Zazzi, K. Theys, 2012, Antimicrobial Agents and Chemotherapy.

Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review

D. Podzamczer, J. Miro, D. Giralt, 2021, BMC Public Health.

ASYMPTOMATIC MONKEY POX VIRUS INFECTION: A SELF-SAMPLING SCREENING INTERVENTION ADRESSED TO GAY, BISEXUAL AND OTHER MEN WHO HAVE SEX WITH MEN AND TRANS WOMEN IN SPAIN

B. Clotet, P. Cardona, S. Martínez-Puchol, 2023, medRxiv.

Primary resistance to integrase strand-transfer inhibitors in Europe.

M. Poljak, R. Paredes, C. Boucher, 2015, The Journal of antimicrobial chemotherapy.

Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.

R. Paredes, L. Ruiz, J. Romeu, 1999, Antiviral therapy.

Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz.

R. Paredes, B. Clotet, L. Ruiz, 2008, The Journal of antimicrobial chemotherapy.

2021 update to HIV-TRePS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings.

B. Gazzard, R. Kaiser, B. Larder, 2021, The Journal of antimicrobial chemotherapy.

2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings

Dechao Wang, Shanmugam Saravanan, John Baxter, 2018, The Journal of antimicrobial chemotherapy.

Psychological impact of structured treatment interruptions in patients with prolonged undetectable HIV-1 viral loads.

R. Paredes, L. Ruiz, J. Romeu, 2001, AIDS.

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group.

L. M. Lehman, J. Leonard, A. Hsu, 1995, The New England journal of medicine.

Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial.

D. Podzamczer, C. Katlama, H. Furrer, 2012, The Journal of antimicrobial chemotherapy.

Long‐term effectiveness of recommended boosted protease inhibitor‐based antiretroviral therapy in Europe

A. Mocroft, A. Blaxhult, J. Lundgren, 2018, HIV medicine.